$IMUX
Immunic Inc Stock $imux

$imux Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000128077624000009 Filed on May 08, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.491M	$5.145M
YoY Change	16.68%	19.99%
% of Gross Profit
Research & Development	$18.32M	$18.74M
YoY Change	-13.46%	-18.41%
% of Gross Profit
Depreciation & Amortization	$31.00K	$26.00K
YoY Change	40.91%	-18.75%
% of Gross Profit
Operating Expenses	$22.81M	$23.88M
YoY Change	-8.82%	-12.37%
Operating Profit	-$22.81M	-$23.88M
YoY Change	-8.82%	-12.37%
Interest Expense	$998.0K	$1.187M
YoY Change	3.1%	48.38%
% of Operating Profit
Other Income/Expense, Net	$1.434M	-$5.703M
YoY Change	2555.56%	-388.18%
Pretax Income	-$21.38M	-$29.58M
YoY Change	-10.91%	17.06%
Income Tax
% Of Pretax Income
Net Earnings	-$21.38M	-$29.58M
YoY Change	-10.91%	17.06%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.21	-$0.30
Diluted Earnings Per Share	-$0.21	-$0.30
COMMON SHARES
Basic Shares Outstanding	90.08M shares	89.93M shares
Diluted Shares Outstanding	101.3M shares	97.30M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$79.70M	$97.31M
YoY Change	3.11%	0.21%
Cash & Equivalents	$79.70M	$97.31M
Short-Term Investments
Other Short-Term Assets	$1.057M	$1.090M
YoY Change	-86.91%	-42.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$84.98M	$102.6M
YoY Change	-1.82%	-3.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$585.0K	$442.0K
YoY Change	-72.73%	53.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.513M	$1.540M
YoY Change	-30.85%	-32.75%
TOTAL ASSETS
Total Short-Term Assets	$84.98M	$102.6M
Total Long-Term Assets	$1.513M	$1.540M
Total Assets	$86.49M	$104.2M
YoY Change	-2.53%	-4.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.894M	$6.767M
YoY Change	67.96%	29.12%
Accrued Expenses	$13.78M	$12.42M
YoY Change	3.7%	21.96%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$22.68M	$20.15M
YoY Change	24.32%	23.58%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$241.0K	$433.0K
YoY Change	-80.15%	-67.97%
Total Long-Term Liabilities	$241.0K	$433.0K
YoY Change	-80.15%	-67.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.68M	$20.15M
Total Long-Term Liabilities	$241.0K	$433.0K
Total Liabilities	$22.92M	$20.58M
YoY Change	17.8%	16.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$461.9M	-$440.5M
YoY Change	26.0%	28.58%
Common Stock	$8.000K	$8.000K
YoY Change	100.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$63.57M	$83.58M
YoY Change
Total Liabilities & Shareholders Equity	$86.49M	$104.2M
YoY Change	-2.53%	-4.33%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$21.38M	-$29.58M
YoY Change	-10.91%	17.06%
Depreciation, Depletion And Amortization	$31.00K	$26.00K
YoY Change	40.91%	-18.75%
Cash From Operating Activities	-$17.03M	-$23.97M
YoY Change	-14.74%	22.84%
INVESTING ACTIVITIES
Capital Expenditures	$180.0K	$31.00K
YoY Change	757.14%	-70.19%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$180.0K	-$31.00K
YoY Change	-104.15%	-100.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$74.46M
YoY Change	-100.0%	145907.84%
NET CHANGE
Cash From Operating Activities	-17.03M	-$23.97M
Cash From Investing Activities	-180.0K	-$31.00K
Cash From Financing Activities	0.000	$74.46M
Net Change In Cash	-17.21M	$50.64M
YoY Change	10.72%	-462.11%
FREE CASH FLOW
Cash From Operating Activities	-$17.03M	-$23.97M
Capital Expenditures	$180.0K	$31.00K
Free Cash Flow	-$17.21M	-$24.00M
YoY Change	-13.93%	22.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense
CY2024Q1	us-gaap	Government Assistance Statement Of Income Or Comprehensive Income Extensible Enumeration GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2024Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	90079016	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90079016	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45177730	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45177730	shares
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5145000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4288000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	23881000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	27251000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-23881000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27251000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1187000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	800000	usd
CY2024Q1	vtl	Fair Value Change In Fair Value Of Tranche Rights Transaction Costs FairValueChangeInFairValueOfTrancheRightsTransactionCosts	4796000	usd
CY2023Q1	vtl	Fair Value Change In Fair Value Of Tranche Rights Transaction Costs FairValueChangeInFairValueOfTrancheRightsTransactionCosts	0	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2094000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1179000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5703000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1979000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-29584000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-25272000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97299955	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97299955	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43664783	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43664783	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-29584000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-25272000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	528000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	776000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29056000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24496000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	28931000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-29584000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2750000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	528000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	28396000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	83576000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	113684000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-25272000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1979000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	776000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	51000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	91218000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-29584000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-25272000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-340000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-516000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2750000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1979000	usd
CY2024Q1	vtl	Change In Fair Value Of Tranche Rights ChangeInFairValueOfTrancheRights	4796000	usd
CY2023Q1	vtl	Change In Fair Value Of Tranche Rights ChangeInFairValueOfTrancheRights	0	usd
CY2024Q1	us-gaap	Management Fee Expense ManagementFeeExpense	1690000	usd
CY2023Q1	us-gaap	Management Fee Expense ManagementFeeExpense	0	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-389000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-123000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1794000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	986000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6145000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2072000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-25000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	51000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23969000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19513000	usd
CY2024Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	0	usd
CY2023Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-5439000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	104000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5335000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	191000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	51000	usd
CY2024Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	74273000	usd
CY2023Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	74464000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	174000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	50638000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13984000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46674000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	106745000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97312000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92761000	usd
CY2024Q1	vtl	Conversion Of Tranche Rights Liability To Equity Upon Increase In Authorized Shares ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares	28396000	usd
CY2023Q1	vtl	Conversion Of Tranche Rights Liability To Equity Upon Increase In Authorized Shares ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares	0	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	544000	usd
CY2024Q1	vtl	Number Of Development Programs NumberOfDevelopmentPrograms	3	lease
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-440500000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-410900000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	430900000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97300000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	32000	usd
CY2024Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements. The most significant estimates in the Company’s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div>
CY2024Q1	vtl	Number Of Financial Institutions Used For Cash Deposits NumberOfFinancialInstitutionsUsedForCashDeposits	2	financialinstitution
CY2024Q1	us-gaap	Depreciation Depreciation	26000	usd
CY2024Q1	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	36000	usd
CY2023Q1	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	1800000	usd
CY2024Q1	vtl	Lessee Operating Leases Number Of Existing Leases LesseeOperatingLeasesNumberOfExistingLeases	3	lease
CY2024Q1	vtl	Prepaid Clinical And Related Costs Current PrepaidClinicalAndRelatedCostsCurrent	2767000	usd
CY2023Q4	vtl	Prepaid Clinical And Related Costs Current PrepaidClinicalAndRelatedCostsCurrent	2314000	usd
CY2024Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	770000	usd
CY2023Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	703000	usd
CY2024Q1	vtl	Government Assistance Qualified Research And Development Expenditures Maximum Amount GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount	676000	usd
CY2023Q4	vtl	Government Assistance Qualified Research And Development Expenditures Maximum Amount GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount	670000	usd
CY2024Q1	vtl	Research And Development Grant ResearchAndDevelopmentGrant	0	usd
CY2023Q4	vtl	Research And Development Grant ResearchAndDevelopmentGrant	1104000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1090000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1069000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5303000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5860000	usd
CY2024Q1	vtl	Clinical Costs Payable Current ClinicalCostsPayableCurrent	6211000	usd
CY2023Q4	vtl	Clinical Costs Payable Current ClinicalCostsPayableCurrent	4726000	usd
CY2024Q1	vtl	Legal And Audit Costs Payable Current LegalAndAuditCostsPayableCurrent	115000	usd
CY2023Q4	vtl	Legal And Audit Costs Payable Current LegalAndAuditCostsPayableCurrent	160000	usd
CY2024Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	441000	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	213000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6767000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5099000	usd
CY2024Q1	vtl	Accrued Clinical Costs Current AccruedClinicalCostsCurrent	11497000	usd
CY2023Q4	vtl	Accrued Clinical Costs Current AccruedClinicalCostsCurrent	16863000	usd
CY2024Q1	vtl	Accrued Legal And Audit Costs Current AccruedLegalAndAuditCostsCurrent	234000	usd
CY2023Q4	vtl	Accrued Legal And Audit Costs Current AccruedLegalAndAuditCostsCurrent	216000	usd
CY2024Q1	vtl	Accrued Compensation Current AccruedCompensationCurrent	610000	usd
CY2023Q4	vtl	Accrued Compensation Current AccruedCompensationCurrent	1460000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	78000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	125000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12419000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18664000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	697000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	695000	usd
CY2024Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	263000	usd
CY2023Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	271000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	960000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	966000	usd
CY2024Q1	vtl	Operating And Variable Leases Cost OperatingAndVariableLeasesCost	257000	usd
CY2023Q1	vtl	Operating And Variable Leases Cost OperatingAndVariableLeasesCost	195000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	551000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	433000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	78000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	82000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	79000	usd
CY2024Q1	vtl	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1223000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	93000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1130000	usd
CY2024Q1	us-gaap	Contractual Obligation ContractualObligation	3000000	usd
CY2024Q1	vtl	Tranche Right Fair Value Disclosure TrancheRightFairValueDisclosure	23600000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	vtl	Fair Value Reclassification Of Future Tranche Right Liability Upon Settlement FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement	4800000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	23600	usd
CY2024Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	4796	usd
CY2024Q1	vtl	Reclassification To Equity ReclassificationToEquity	-28396	usd
CY2024Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	usd
CY2024Q1	vtl	Shelf Registration Agreement Commission Percent Of Gross Proceeds On Sale Of Common Stock ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock	0.030
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	vtl	Number Of Votes Per Each Share Of Common Stock NumberOfVotesPerEachShareOfCommonStock	1	numberofvote
CY2024Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0
CY2024Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	124973057	shares
CY2024Q1	vtl	Share Based Compensation By Share Based Payment Award Options Repriced Number Of Shares ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares	3317596	shares
CY2024Q1	vtl	Share Based Payment Arrangement Plan Modification Option Exercise Price ShareBasedPaymentArrangementPlanModificationOptionExercisePrice	1.72
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	1200000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	900000	usd
CY2024Q1	vtl	Share Based Compensation Arrangement By Share Based Payment Award Options Repricing Modification In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod	0	shares
CY2024Q1	vtl	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Repricing Modifications Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice	9.55
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q1	vtl	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value For Repriced Stock Options ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions	1.22

Files In Submission

Name	View Source	Status
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vtl-20240331.htm	Edgar Link	pending
vtl-20240331.xsd	Edgar Link	pending
vtl-20240331_g1.jpg	Edgar Link	pending
vtl-20240331_def.xml	Edgar Link	unprocessable
vtl-20240331_htm.xml	Edgar Link	completed
0001280776-24-000009-index-headers.html	Edgar Link	pending
0001280776-24-000009-index.html	Edgar Link	pending
0001280776-24-000009.txt	Edgar Link	pending
0001280776-24-000009-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
imux-33124xexhibit311.htm	Edgar Link	pending
imux-33124xexhibit312.htm	Edgar Link	pending
imux-33124xexhibit322.htm	Edgar Link	pending
imux-3x31x24xexhibit321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
vtl-20240331_cal.xml	Edgar Link	unprocessable
vtl-20240331_lab.xml	Edgar Link	unprocessable
vtl-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IMUX
Immunic Inc Stock $imux

2024 Q2 Form 10-Q Financial Statement

#000128077624000009 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMUX Immunic Inc Stock $imux

2024 Q2 Form 10-Q Financial Statement

#000128077624000009 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMUX
Immunic Inc Stock $imux